NASDAQ: CARMCarisma Therapeutics Inc Stock
$0.19+0.00 (+0%)
Updated Apr 21, 2025
CARM Price
$0.19
Fair Value Price
N/A
Market Cap
$7.90M
52 Week Low
$0.16
52 Week High
$1.91
P/E
-0.13x
P/B
-0.28x
P/S
0.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$19.63M
Earnings
-$60.48M
Gross Margin
100%
Operating Margin
-308.05%
Profit Margin
-308.1%
Debt to Equity
-2.09
Operating Cash Flow
-$60M
Beta
1.17
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CARM Overview
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CARM's potential to beat the market
- CARM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CARM
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important CARM news, forecast changes, insider trades & much more!
CARM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CARM scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CARM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CARM is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CARM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 35 more CARM due diligence checks available for Premium users.
Valuation
CARM fair value
Fair Value of CARM stock based on Discounted Cash Flow (DCF)
Price
$0.19
Fair Value
$0.37
Undervalued by
48.95%
CARM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CARM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.13x
Industry
-184.27x
Market
27.14x
CARM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.28x
Industry
4.04x
CARM's financial health
Profit margin
Revenue
$3.7M
Net Income
-$17.6M
Profit Margin
-482.8%
CARM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CARM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$30.5M
Liabilities
$58.4M
Debt to equity
-2.09
CARM's short-term assets ($23.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CARM's long-term liabilities ($42.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CARM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CARM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.4M
Investing
$0.0
Financing
-$620.0k
CARM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CARM vs Biotech Stocks
Carisma Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.